Gerl A - Search Results

1

Management and outcome of bilateral testicular germ cell tumors: Twenty-five year experience in Munich.

Hentrich M, Weber N, Bergsdorf T, Liedl B, Hartenstein R, Gerl A. Hentrich M, et al. Among authors: gerl a. Acta Oncol. 2005;44(6):529-36. doi: 10.1080/02841860510029923. Acta Oncol. 2005. PMID: 16165911 Review.

2

Etoposide, cisplatin, bleomycin, and cyclophosphamide (ECBC) as first-line chemotherapy for poor-risk non-seminomatous germ cell tumors.

Gerl A, Clemm C, Hentrich M, Hartenstein R, Wilmanns W. Gerl A, et al. Acta Oncol. 1993;32(5):541-6. doi: 10.3109/02841869309096115. Acta Oncol. 1993. PMID: 7692901

3

Improved outcomes in metastatic germ cell cancer: results from a large cohort study.

Hentrich M, Debole J, Jurinovic V, Gerl A. Hentrich M, et al. Among authors: gerl a. J Cancer Res Clin Oncol. 2021 Feb;147(2):533-538. doi: 10.1007/s00432-020-03343-2. Epub 2020 Aug 9. J Cancer Res Clin Oncol. 2021. PMID: 32772232 Free PMC article.

4

Smoking cessation in long-term survivors of germ cell tumour.

Hentrich M, Fegg MJ, Meiler S, Jost C, Gerl A. Hentrich M, et al. Among authors: gerl a. J Cancer Res Clin Oncol. 2006 Sep;132(9):557-60. doi: 10.1007/s00432-006-0102-z. Epub 2006 Jun 2. J Cancer Res Clin Oncol. 2006. PMID: 16741728

5

Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: a single-institution experience.

Gerl A, Clemm C, Schmeller N, Hartenstein R, Lamerz R, Wilmanns W. Gerl A, et al. Br J Cancer. 1996 Oct;74(8):1280-5. doi: 10.1038/bjc.1996.530. Br J Cancer. 1996. PMID: 8883418 Free PMC article. Clinical Trial.

6

Late relapse of germ cell tumors after cisplatin-based chemotherapy.

Gerl A, Clemm C, Schmeller N, Hentrich M, Lamerz R, Wilmanns W. Gerl A, et al. Ann Oncol. 1997 Jan;8(1):41-7. doi: 10.1023/a:1008253323854. Ann Oncol. 1997. PMID: 9093706 Free article. Review.

7

Intermediate prognosis in metastatic germ cell tumours-outcome and prognostic factors.

Seidel C, Daugaard G, Tryakin A, Necchi A, Cohn Cedermark G, Ståhl O, Hentrich M, Brito M, Albany C, Taza F, Gerl A, Oechsle K, Bokemeyer C. Seidel C, et al. Among authors: gerl a. Eur J Cancer. 2018 May;94:16-25. doi: 10.1016/j.ejca.2018.01.113. Epub 2018 Mar 20. Eur J Cancer. 2018. PMID: 29505967

8

Prognosis after salvage treatment for unselected male patients with germ cell tumours.

Gerl A, Clemm C, Schmeller N, Hartenstein R, Lamerz R, Wilmanns W. Gerl A, et al. Br J Cancer. 1995 Oct;72(4):1026-32. doi: 10.1038/bjc.1995.456. Br J Cancer. 1995. PMID: 7547217 Free PMC article.

9

The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).

Seidel C, Daugaard G, Tryakin A, Necchi A, Cohn-Cedermark G, Ståhl O, Hentrich M, Brito M, Albany C, Taza F, Gerl A, Oechsle K, Oing C, Bokemeyer C. Seidel C, et al. Among authors: gerl a. Urol Oncol. 2019 Nov;37(11):809.e19-809.e25. doi: 10.1016/j.urolonc.2019.07.020. Epub 2019 Sep 5. Urol Oncol. 2019. PMID: 31494007

10

Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors?

Gerl A, Lamerz R, Clemm C, Mann K, Hartenstein R, Wilmanns W. Gerl A, et al. Clin Cancer Res. 1996 Sep;2(9):1565-70. Clin Cancer Res. 1996. PMID: 9816334

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

97 results

Search Page

Filters